Modulatory Role of Galectin-1 in Ulcerative Colitis with Comorbid Metabolic Syndrome

Metabolic syndrome (MetS) and ulcerative colitis (UC) are widespread health conditions characterized by chronic, low-grade inflammation. Galectin-1 (Gal-1), an immunomodulatory peptide mainly secreted from adipose tissue, could potentially play a crucial role in mitigating these conditions. This cro...

Full description

Saved in:
Bibliographic Details
Published inExperimental and Applied Biomedical Research (EABR)
Main Authors Corovic, Kemal, Stojanovic, Bojan, Petrovic, Andjela, Stanisavljevic, Isidora, Maric, Veljko, Zdravkovic, Natasa, Jovanovic, Marina
Format Journal Article
LanguageEnglish
Published 01.08.2023
Online AccessGet full text

Cover

More Information
Summary:Metabolic syndrome (MetS) and ulcerative colitis (UC) are widespread health conditions characterized by chronic, low-grade inflammation. Galectin-1 (Gal-1), an immunomodulatory peptide mainly secreted from adipose tissue, could potentially play a crucial role in mitigating these conditions. This cross-sectional study explores the involvement of Gal-1 in MetS and UC within a cohort of 75 patients, newly diagnosed with UC. The MetS subgroup displayed increased fecal Gal-1 levels compared to those without MetS. Furthermore, Gal-1 showed predominance over pro-inflammatory cytokines, including TNF-α, IL-6, and IL-17, in these subjects. These findings emphasize the potential involvement of Gal-1 in the pathophysiology of UC and MetS, presenting it as a promising diagnostic biomarker and therapeutic target for these conditions.
ISSN:2956-0454
2956-0454
DOI:10.2478/eabr-2023-0006